Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation and long-term operational performance.
The new company brings together the clinical, operational, research and education expertise of Penn Medicine with IBA's global leadership in proton therapy technology, project development, and implementation capabilities. The joint venture will provide integrated advisory and lifecycle support services that help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs.
As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems around the world are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.
Proton Therapy Expertise
"By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs," said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.
"A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption" added Henri de Romrée, Deputy CEO of IBA.
Unlike traditional advisory models, the joint venture combines the perspectives of a world-leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.
Visit Noventra’s website to learn more about Noventra’s services.
September 24, 2026 
